Therapy for Hormone Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer Following Treatment Progression via CDK4/6 Inhibitors: A Literature Review

Meixi Ye,1 Hao Xu,1,* Jinhua Ding,2,* Li Jiang3 1The Affiliated Lihuili Hospital, Ningbo University, Ningbo, 315040, People’s Republic of China; 2Department of Breast and Thyroid Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo, 315040, People’s Republic of China; 3Department of General Practice, Ningbo Medical Center Lihuili Hospital, Ningbo, 315040, People’s Republic of China*These authors contributed equally to this workCorrespondence: Li Jiang, Department of General Practice, Ningbo Medical Center Lihuili Hospital, Road Jiangnan, Yinzhou Distract, Ningbo, 315040, People’s Republic of China, Tel +86 13957498692, Email lijiang_1212@163.comAbstract: Endocrine therapy (ET) with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) is currently the first-line standard treatment for most patients with hormone receptor-positive (HR+) and human epidermal growth receptor 2-negative (HER2-) metastatic or advanced breast cancer. However, the majority of tumors response to and eventually develop resistance to CDK4/6is. The mechanisms of resistance are poorly understood, and the optimal postprogression treatment regimens and their sequences continue to evolve in the rapidly changing treatment landscape. In this review, we generally summarize the mechanisms of resistance to CDK4/6is and ET, and describe the findings from clinical trials using small molecule inhibitors, antibody-drug conjugates and immunotherapy, providing insights into how these novel strategies may reverse treatment resistance, and discussing how some have not translated into clinical benefit. Finally, we provide rational treatment strategies based on the current emerging evidence.Keywords: breast cancer, human epidermal growth receptor 2, hormone receptor, cyclin- dependent kinases 4 and 6 inhibitor, endocrine resistance, molecular mechanism